Home News Generic semaglutide launches in India and Canada
Generic semaglutide launches in India and Canada — US patients wait until 2031
Indian generics started at about $8 a month in March. FDA has tentatively approved a US version that cannot legally be sold for another five years.
Market2026-08-06
Indian generics started at about $8 a month in March. FDA has tentatively approved a US version that cannot legally be sold for another five years.
Semaglutide patents expired in India on 20 March 2026 and generics launched within weeks from Sun Pharma, Dr Reddy's, Zydus, Lupin and Mankind, with prices reported from about $8 a month. Health Canada approved its first two generics in April and May 2026, with the Canadian market expected to take shape in the third quarter.
By the end of 2026 core semaglutide patents will have lapsed in around ten countries including Brazil, China, South Africa, Turkey and Canada — markets holding roughly a third of the world's adults with obesity.
The United States is not among them. Novo Nordisk's core US compound patent runs to December 2031 with formulation patents extending into 2032, protected by a thicket of more than 220 filings largely covering delivery devices. Apotex received the first FDA tentative approval for a generic semaglutide injection in April 2026, which confirms the product meets every FDA standard and still cannot be sold.
For tirzepatide specifically this changes little: it is a newer molecule with later patent expiry, and no comparable generic wave is near. The indirect pressure is real but slow, and it is visible in the 13% decline in realised prices Lilly reported for the second quarter.
Personal importation of prescription medicines into the US is generally unlawful, and FDA has been explicit that products from foreign online sellers frequently are not what they claim to be.
Sources
- Indian and Canadian generic approvals and launches, March to May 2026, as reported
- FDA tentative approval for generic semaglutide injection, April 2026
Dated 2026-08-06. If this item is out of date or wrong, tell us through contact and the change is logged in corrections.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.